[{"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-001", "question": "A 52-year-old woman with primary sclerosing cholangitis and ulcerative colitis presents with progressive fatigue and pruritus. Laboratory studies show alkaline phosphatase 892 U/L, total bilirubin 4.2 mg/dL, and CA 19-9 of 285 U/mL. MRCP reveals a dominant stricture at the hepatic duct bifurcation with upstream biliary dilation. Brush cytology obtained during ERCP shows atypical cells suspicious for malignancy. Fluorescence in situ hybridization (FISH) analysis demonstrates polysomy. Which additional finding on FISH would most strongly support a diagnosis of cholangiocarcinoma over reactive atypia in this clinical context?", "options": ["Homozygous deletion of 9p21 (CDKN2A/p16)", "Trisomy of chromosome 7", "Monosomy of chromosome 17", "Gain of chromosome 3", "Deletion of 1p36"], "answer": "A", "answer_index": 0, "explanation": "Homozygous deletion of 9p21 (CDKN2A/p16) detected by FISH has the highest specificity (approaching 100%) for cholangiocarcinoma in the setting of PSC with indeterminate biliary strictures. While polysomy alone increases suspicion for malignancy, it can occur in reactive conditions. Trisomy 7 and other chromosomal gains are less specific. The combination of polysomy plus 9p21 homozygous deletion essentially confirms malignancy in this high-risk population.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues driving unique best answer include PSC history with ulcerative colitis, progressive symptoms, elevated ALP/bilirubin/CA19-9, dominant stricture on MRCP with dilation, atypical cytology suspicious for malignancy, and baseline FISH polysomy—all heightening suspicion for cholangiocarcinoma but requiring differentiation from reactive atypia in PSC. The question asks for the additional FISH finding most strongly supporting malignancy over benign changes. Homozygous 9p21 deletion (A) fits best due to its near-100% specificity for cholangiocarcinoma in PSC-related indeterminate strictures, per established literature, building on polysomy's sensitivity but lower specificity. Alternatives are inferior: Trisomy 7 (B) and gains like chromosome 3 (D) are less specific aneuploidies seen in reactive states; Monosomy 17 (C) and 1p36 deletion (E) lack strong association with cholangiocarcinoma specificity in this context. No main logical issues; stem provides sufficient discriminating details without contradictions or underspecification, allowing unique best answer. No main medical accuracy issues; aligns with current guidelines (e.g., ASGE on biliary strictures in PSC) emphasizing 9p21 deletion's diagnostic value. Minimal fix: None needed; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues driving unique best answer include PSC history with ulcerative colitis, progressive symptoms, elevated ALP/bilirubin/CA19-9, dominant stricture on MRCP with dilation, atypical cytology suspicious for malignancy, and baseline FISH polysomy—all heightening suspicion for cholangiocarcinoma but requiring differentiation from reactive atypia in PSC. The question asks for the additional FISH finding most strongly supporting malignancy over benign changes. Homozygous 9p21 deletion (A) fits best due to its near-100% specificity for cholangiocarcinoma in PSC-related indeterminate strictures, per established literature, building on polysomy's sensitivity but lower specificity. Alternatives are inferior: Trisomy 7 (B) and gains like chromosome 3 (D) are less specific aneuploidies seen in reactive states; Monosomy 17 (C) and 1p36 deletion (E) lack strong association with cholangiocarcinoma specificity in this context. No main logical issues; stem provides sufficient discriminating details without contradictions or underspecification, allowing unique best answer. No main medical accuracy issues; aligns with current guidelines (e.g., ASGE on biliary strictures in PSC) emphasizing 9p21 deletion's diagnostic value. Minimal fix: None needed; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-002", "question": "A 38-year-old man undergoes evaluation for chronic diarrhea and weight loss. Small bowel biopsy reveals villous atrophy with increased intraepithelial lymphocytes. Despite strict gluten-free diet adherence confirmed by negative tissue transglutaminase antibodies for 18 months, symptoms persist. Repeat biopsy shows persistent villous atrophy with aberrant intraepithelial lymphocytes lacking surface CD3 but expressing cytoplasmic CD3, CD7, and CD103, with loss of CD8. T-cell receptor gene rearrangement studies show a monoclonal population. Which therapeutic approach offers the best chance of inducing remission before consideration of autologous stem cell transplantation?", "options": ["Budesonide 9 mg daily", "Cladribine-based chemotherapy", "Infliximab induction and maintenance", "Azathioprine 2.5 mg/kg daily", "Mesalamine 4.8 g daily"], "answer": "B", "answer_index": 1, "explanation": "This patient has Type II refractory celiac disease (RCD II), characterized by aberrant intraepithelial lymphocytes with the described immunophenotype (surface CD3-negative, cytoplasmic CD3-positive, CD8 loss) and monoclonal TCR rearrangement. RCD II has high risk of progression to enteropathy-associated T-cell lymphoma. Cladribine (2-CdA), a purine analog, has shown the best response rates (approximately 40-50%) in inducing histologic and clinical remission in RCD II and serves as a bridge to autologous stem cell transplantation. Steroids, immunomodulators, and biologics used in RCD I are ineffective in RCD II.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include persistent villous atrophy despite confirmed strict gluten-free diet for 18 months, aberrant intraepithelial lymphocytes lacking surface CD3 but expressing cytoplasmic CD3, CD7, CD103 with CD8 loss, and monoclonal T-cell receptor gene rearrangement, pointing to refractory celiac disease type II (RCD II) with risk of lymphoma progression. The question asks for the best therapeutic approach to induce remission before autologous stem cell transplantation. Main logical issue(s): None; the stem provides sufficient discriminating details to identify cladribine-based chemotherapy as the single best option, with alternatives less effective for RCD II. Main medical accuracy issue(s): None; the immunophenotype and clonality accurately characterize RCD II, and cladribine is supported by current evidence (e.g., response rates ~40-50% in studies) as a bridge therapy, consistent with guidelines from societies like the American Gastroenterological Association. Budesonide and azathioprine are more suitable for RCD I, infliximab and mesalamine for inflammatory bowel diseases. Minimal fix: No edit needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include persistent villous atrophy despite confirmed strict gluten-free diet for 18 months, aberrant intraepithelial lymphocytes lacking surface CD3 but expressing cytoplasmic CD3, CD7, CD103 with CD8 loss, and monoclonal T-cell receptor gene rearrangement, pointing to refractory celiac disease type II (RCD II) with risk of lymphoma progression. The question asks for the best therapeutic approach to induce remission before autologous stem cell transplantation. Main logical issue(s): None; the stem provides sufficient discriminating details to identify cladribine-based chemotherapy as the single best option, with alternatives less effective for RCD II. Main medical accuracy issue(s): None; the immunophenotype and clonality accurately characterize RCD II, and cladribine is supported by current evidence (e.g., response rates ~40-50% in studies) as a bridge therapy, consistent with guidelines from societies like the American Gastroenterological Association. Budesonide and azathioprine are more suitable for RCD I, infliximab and mesalamine for inflammatory bowel diseases. Minimal fix: No edit needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-003", "question": "A 45-year-old woman with lupus nephritis class IV on mycophenolate mofetil and prednisone develops acute kidney injury with serum creatinine rising from 1.2 to 3.8 mg/dL over 2 weeks. Urinalysis shows 3+ protein, numerous dysmorphic RBCs, and RBC casts. Complement levels are normal and anti-dsDNA titers are stable. Kidney biopsy reveals crescentic glomerulonephritis with linear IgG staining along the glomerular basement membrane, with concurrent immune complex deposits in the mesangium. Anti-GBM antibodies are positive at 85 EU (normal <20). Which statement best characterizes this clinical entity?", "options": ["This represents lupus flare requiring intensification of immunosuppression alone", "The linear IgG staining is an artifact from prior immune complex deposition", "This is anti-GBM disease superimposed on lupus nephritis requiring plasmapheresis", "Concurrent ANCA-associated vasculitis is the most likely explanation", "The anti-GBM antibodies are false-positive due to cross-reactivity with dsDNA"], "answer": "C", "answer_index": 2, "explanation": "This patient has developed anti-GBM disease superimposed on pre-existing lupus nephritis, a rare but well-documented phenomenon. The linear IgG staining pattern is pathognomonic for anti-GBM disease and distinct from the granular pattern of lupus nephritis. The presence of positive anti-GBM antibodies confirms the diagnosis. Treatment requires plasmapheresis to remove circulating anti-GBM antibodies in addition to immunosuppression. Normal complements and stable anti-dsDNA argue against lupus flare as the sole explanation. Anti-GBM antibodies target the NC1 domain of type IV collagen and do not cross-react with dsDNA.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include acute kidney injury with rising creatinine, urinalysis showing proteinuria, dysmorphic RBCs and casts, normal complements, stable anti-dsDNA titers, biopsy revealing crescentic glomerulonephritis with linear IgG staining along the glomerular basement membrane plus mesangial immune complex deposits, and positive anti-GBM antibodies at 85 EU. These findings support anti-GBM disease superimposed on lupus nephritis, as linear IgG is pathognomonic for anti-GBM, distinct from lupus's granular pattern, with normal complements/stable anti-dsDNA arguing against isolated lupus flare. The question asks for the best characterization of this entity, implying a rare overlap syndrome requiring specific management like plasmapheresis. Main logical issue(s): None; the stem provides sufficient discriminating details for a single best answer without contradictions or underspecification. Main medical accuracy issue(s): None; this aligns with established knowledge of anti-GBM disease co-occurring with lupus nephritis, where treatment involves plasmapheresis plus immunosuppression, consistent with guidelines. Anti-GBM antibodies target type IV collagen without dsDNA cross-reactivity. Minimal fix: No edit needed; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include acute kidney injury with rising creatinine, urinalysis showing proteinuria, dysmorphic RBCs and casts, normal complements, stable anti-dsDNA titers, biopsy revealing crescentic glomerulonephritis with linear IgG staining along the glomerular basement membrane plus mesangial immune complex deposits, and positive anti-GBM antibodies at 85 EU. These findings support anti-GBM disease superimposed on lupus nephritis, as linear IgG is pathognomonic for anti-GBM, distinct from lupus's granular pattern, with normal complements/stable anti-dsDNA arguing against isolated lupus flare. The question asks for the best characterization of this entity, implying a rare overlap syndrome requiring specific management like plasmapheresis. Main logical issue(s): None; the stem provides sufficient discriminating details for a single best answer without contradictions or underspecification. Main medical accuracy issue(s): None; this aligns with established knowledge of anti-GBM disease co-occurring with lupus nephritis, where treatment involves plasmapheresis plus immunosuppression, consistent with guidelines. Anti-GBM antibodies target type IV collagen without dsDNA cross-reactivity. Minimal fix: No edit needed; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-004", "question": "A 62-year-old man with myelodysplastic syndrome with excess blasts-2 (MDS-EB2) undergoes allogeneic hematopoietic stem cell transplantation from a matched unrelated donor. On day +45, he develops progressive pancytopenia with WBC 0.8 × 10⁹/L, hemoglobin 7.2 g/dL, and platelets 12 × 10⁹/L. Bone marrow biopsy shows hypocellularity (10%) with no evidence of relapsed MDS. Chimerism analysis reveals 100% donor cells. Cytomegalovirus and HHV-6 PCR are negative. Which mechanism most likely explains this patient's graft failure?", "options": ["Donor-derived clonal hematopoiesis with DDX41 germline mutation", "Secondary hemophagocytic lymphohistiocytosis", "Graft-versus-host disease affecting the bone marrow stroma", "Residual host T-cell mediated rejection despite full donor chimerism", "Drug-induced marrow suppression from valganciclovir prophylaxis"], "answer": "A", "answer_index": 0, "explanation": "Donor-derived clonal hematopoiesis from germline mutations (particularly DDX41) in the donor can cause graft failure or donor-derived MDS/AML post-transplant. DDX41 mutations are increasingly recognized as a cause of familial MDS/AML and can be present in phenotypically normal donors. The 100% donor chimerism excludes host-mediated rejection. The absence of CMV/HHV-6 and the clinical context make drug toxicity less likely. HLH would typically show additional features (ferritin elevation, hepatosplenomegaly). Marrow stromal GVHD is rare and would not explain isolated hematopoietic failure with full donor chimerism.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: progressive pancytopenia at day +45 post-allo HSCT, bone marrow hypocellularity (10%) without MDS relapse, 100% donor chimerism, and negative CMV/HHV-6 PCR, pointing to a donor-related mechanism for secondary graft failure while excluding host rejection, active viral infection, and relapse. Main logical issue(s), if any: None; the stem provides sufficient discriminating details to rule out alternatives—full donor chimerism contradicts D (rejection), absence of additional HLH features (e.g., no mention of ferritin or organomegaly) makes B less defensible, stromal GVHD (C) is rare and not isolated to hypocellularity, and E assumes unstated valganciclovir use, which the stem does not specify, rendering it unsupported without assumption. A is uniquely supported as a recognized mechanism via donor-derived clonal hematopoiesis (e.g., DDX41). Main medical accuracy issue(s), if any: None; aligns with current hematology standards on DDX41-associated graft failure in transplants from unaffected carriers, consistent with guidelines from ASBMT/EBMT and recent literature on donor germline mutations. Minimal fix: No fix needed; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: progressive pancytopenia at day +45 post-allo HSCT, bone marrow hypocellularity (10%) without MDS relapse, 100% donor chimerism, and negative CMV/HHV-6 PCR, pointing to a donor-related mechanism for secondary graft failure while excluding host rejection, active viral infection, and relapse. Main logical issue(s), if any: None; the stem provides sufficient discriminating details to rule out alternatives—full donor chimerism contradicts D (rejection), absence of additional HLH features (e.g., no mention of ferritin or organomegaly) makes B less defensible, stromal GVHD (C) is rare and not isolated to hypocellularity, and E assumes unstated valganciclovir use, which the stem does not specify, rendering it unsupported without assumption. A is uniquely supported as a recognized mechanism via donor-derived clonal hematopoiesis (e.g., DDX41). Main medical accuracy issue(s), if any: None; aligns with current hematology standards on DDX41-associated graft failure in transplants from unaffected carriers, consistent with guidelines from ASBMT/EBMT and recent literature on donor germline mutations. Minimal fix: No fix needed; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-005", "question": "A 28-year-old woman presents with recurrent sinopulmonary infections since childhood, chronic diarrhea, and splenomegaly. Laboratory evaluation reveals IgG 180 mg/dL (normal 700-1600), IgA <7 mg/dL, IgM 320 mg/dL (normal 40-230), and absent isohemagglutinins. Flow cytometry shows normal B-cell numbers but absent CD27+ memory B cells. Genetic testing reveals a hemizygous mutation in CD40LG. Her brother has similar symptoms. Which finding would be most unexpected in this patient?", "options": ["Cryptosporidium parvum cholangiopathy", "Pneumocystis jirovecii pneumonia", "Germinal center formation on lymph node biopsy", "Neutropenia", "Elevated liver enzymes"], "answer": "C", "answer_index": 2, "explanation": "This patient has X-linked hyper-IgM syndrome (HIGM1) due to CD40LG mutation, which can occur in females due to skewed X-inactivation or homozygosity. CD40L-CD40 interaction is essential for germinal center formation, class-switch recombination, and somatic hypermutation. Therefore, germinal center formation would be absent on lymph node biopsy. Cryptosporidium cholangiopathy, PCP, neutropenia (due to impaired granulopoiesis), and elevated liver enzymes (from sclerosing cholangitis or hepatitis) are all well-documented complications of HIGM1.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: recurrent sinopulmonary infections since childhood, chronic diarrhea, splenomegaly, low IgG and IgA with elevated IgM, absent isohemagglutinins and CD27+ memory B cells despite normal B-cell numbers, hemizygous CD40LG mutation, and affected brother, collectively diagnostic of X-linked hyper-IgM syndrome (HIGM1) with impaired CD40L-CD40 signaling. Main logical issue(s), if any: None; the vignette supports C as the uniquely unexpected finding (germinal centers require CD40L interaction, absent in HIGM1), while A, B, D, and E are documented complications (Cryptosporidium cholangiopathy, PCP, neutropenia, elevated liver enzymes from sclerosing cholangitis). Alternatives are inferior: A/B reflect opportunistic infections, D hematologic issues, E liver involvement—all expected. Main medical accuracy issue(s), if any: Overall consistent with HIGM1 pathophysiology and complications per guidelines (e.g., IDSA for infections, hematology texts for neutropenia); however, 'hemizygous mutation' is terminologically inaccurate for a female (should be heterozygous with skewed X-inactivation or homozygous), as hemizygosity applies to males. This is a minor nonstandard usage but does not alter the diagnosis or answer. Minimal fix: Revise stem to 'heterozygous mutation in CD40LG with skewed X-inactivation.' The clinical problem asks for the least expected finding in HIGM1; key clues imply defective class-switching and germinal center absence, making C unfit while others align.\",\n  \"medical_accuracy_score\": 3,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: recurrent sinopulmonary infections since childhood, chronic diarrhea, splenomegaly, low IgG and IgA with elevated IgM, absent isohemagglutinins and CD27+ memory B cells despite normal B-cell numbers, hemizygous CD40LG mutation, and affected brother, collectively diagnostic of X-linked hyper-IgM syndrome (HIGM1) with impaired CD40L-CD40 signaling. Main logical issue(s), if any: None; the vignette supports C as the uniquely unexpected finding (germinal centers require CD40L interaction, absent in HIGM1), while A, B, D, and E are documented complications (Cryptosporidium cholangiopathy, PCP, neutropenia, elevated liver enzymes from sclerosing cholangitis). Alternatives are inferior: A/B reflect opportunistic infections, D hematologic issues, E liver involvement—all expected. Main medical accuracy issue(s), if any: Overall consistent with HIGM1 pathophysiology and complications per guidelines (e.g., IDSA for infections, hematology texts for neutropenia); however, 'hemizygous mutation' is terminologically inaccurate for a female (should be heterozygous with skewed X-inactivation or homozygous), as hemizygosity applies to males. This is a minor nonstandard usage but does not alter the diagnosis or answer. Minimal fix: Revise stem to 'heterozygous mutation in CD40LG with skewed X-inactivation.' The clinical problem asks for the least expected finding in HIGM1; key clues imply defective class-switching and germinal center absence, making C unfit while others align.", "medical_accuracy_score": 3, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-006", "question": "A 34-year-old man from the Ohio River Valley presents with 3 weeks of fever, night sweats, and 15-pound weight loss. He has a history of HIV infection with CD4 count of 45 cells/μL and is not on antiretroviral therapy. Physical examination reveals hepatosplenomegaly and diffuse lymphadenopathy. Laboratory studies show pancytopenia and LDH 1,850 U/L. Bone marrow biopsy reveals small intracellular yeast forms within macrophages. Urine Histoplasma antigen is strongly positive. He is started on liposomal amphotericin B. On day 3 of treatment, he develops high fever, hypotension, and worsening respiratory status despite negative blood cultures and improving fungal markers. Which intervention is most appropriate?", "options": ["Add voriconazole for possible amphotericin-resistant Histoplasma", "Initiate corticosteroids for immune reconstitution inflammatory syndrome", "Switch to itraconazole due to amphotericin B toxicity", "Add broad-spectrum antibiotics for bacterial superinfection", "Delay antiretroviral therapy initiation for at least 4 weeks"], "answer": "B", "answer_index": 1, "explanation": "This patient is experiencing paradoxical worsening consistent with immune reconstitution inflammatory syndrome (IRIS), which can occur in severely immunocompromised HIV patients even before ART initiation (unmasking IRIS) or represent early inflammatory response to effective antifungal therapy. The improving fungal markers argue against treatment failure or resistance. Corticosteroids (prednisone 0.5-1 mg/kg) are the treatment of choice for moderate-to-severe IRIS. While ART timing is important, the immediate management of IRIS takes precedence. Amphotericin B resistance in Histoplasma is exceedingly rare.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Endemic area (Ohio River Valley), severe HIV immunosuppression (CD4 45, not on ART), confirmed disseminated histoplasmosis (biopsy yeast forms, positive urine antigen), treatment with liposomal amphotericin B, day 3 paradoxical worsening (fever, hypotension, respiratory decline) despite negative blood cultures and improving fungal markers. These support an inflammatory response like IRIS as the cause, making corticosteroids the most appropriate intervention. Main logical issue(s), if any: None; stem provides sufficient discriminating details for B as unique best, with alternatives inferior (A: resistance rare and contradicted by improving markers; C: presentation atypical for amphotericin toxicity; D: negative cultures argue against superinfection; E: not immediate management for acute worsening and assumes ART not yet started). Main medical accuracy issue(s), if any: Mostly consistent with guidelines for managing severe inflammatory responses in histoplasmosis-associated IRIS in HIV, where steroids are indicated for moderate-to-severe cases; however, IRIS is typically linked to ART initiation, and stem's ambiguity on post-presentation ART status slightly muddles terminology (rationale's 'unmasking IRIS before ART' is nonstandard). Minimal fix: Add to stem 'and antiretroviral therapy is initiated concurrently' to unambiguously establish paradoxical IRIS post-ART.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Endemic area (Ohio River Valley), severe HIV immunosuppression (CD4 45, not on ART), confirmed disseminated histoplasmosis (biopsy yeast forms, positive urine antigen), treatment with liposomal amphotericin B, day 3 paradoxical worsening (fever, hypotension, respiratory decline) despite negative blood cultures and improving fungal markers. These support an inflammatory response like IRIS as the cause, making corticosteroids the most appropriate intervention. Main logical issue(s), if any: None; stem provides sufficient discriminating details for B as unique best, with alternatives inferior (A: resistance rare and contradicted by improving markers; C: presentation atypical for amphotericin toxicity; D: negative cultures argue against superinfection; E: not immediate management for acute worsening and assumes ART not yet started). Main medical accuracy issue(s), if any: Mostly consistent with guidelines for managing severe inflammatory responses in histoplasmosis-associated IRIS in HIV, where steroids are indicated for moderate-to-severe cases; however, IRIS is typically linked to ART initiation, and stem's ambiguity on post-presentation ART status slightly muddles terminology (rationale's 'unmasking IRIS before ART' is nonstandard). Minimal fix: Add to stem 'and antiretroviral therapy is initiated concurrently' to unambiguously establish paradoxical IRIS post-ART.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-007", "question": "A 58-year-old woman with metastatic HER2-positive breast cancer on trastuzumab deruxtecan develops progressive dyspnea over 4 weeks. CT chest reveals bilateral ground-glass opacities with a peripheral and lower lobe predominant distribution. Bronchoalveolar lavage shows lymphocytic predominance with CD4/CD8 ratio of 0.5. Infectious workup is negative. She is diagnosed with drug-induced interstitial lung disease. After drug discontinuation and corticosteroid initiation, her symptoms improve. Three months later, restaging shows disease progression. Which factor most strongly supports rechallenge with trastuzumab deruxtecan?", "options": ["Initial ILD grade was 1 with complete radiographic resolution", "Absence of anti-drug antibodies on serologic testing", "HER2 amplification ratio >6 on repeat biopsy", "Negative rechallenge skin testing to the drug", "Normal pulmonary function tests at baseline before rechallenge"], "answer": "A", "answer_index": 0, "explanation": "Rechallenge with trastuzumab deruxtecan after ILD is a complex decision. Per consensus guidelines, rechallenge may be considered only in patients who experienced Grade 1 ILD that completely resolved both clinically and radiographically. Higher grade ILD (Grade 2-4) is generally considered a contraindication to rechallenge. Anti-drug antibodies, HER2 status, skin testing, and baseline PFTs do not reliably predict ILD recurrence risk. The mechanism of T-DXd-associated ILD is not fully understood but appears related to the topoisomerase I inhibitor payload rather than immune-mediated hypersensitivity.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include a 58-year-old woman with metastatic HER2-positive breast cancer who developed drug-induced interstitial lung disease (ILD) on trastuzumab deruxtecan (T-DXd), characterized by progressive dyspnea, bilateral peripheral/lower lobe ground-glass opacities, lymphocytic BAL with low CD4/CD8 ratio, negative infectious workup, and symptom improvement after drug discontinuation and corticosteroids; three months later, restaging shows disease progression, prompting consideration of rechallenge. The clinical problem asks for the factor most strongly supporting T-DXd rechallenge. Discriminating findings imply resolved ILD in progressing cancer, where guidelines favor rechallenge only for prior Grade 1 ILD with complete resolution (option A). Alternatives are inferior: B (anti-drug antibodies not predictive), C (HER2 status irrelevant to ILD risk), D (skin testing not validated for ILD), E (baseline PFTs do not predict recurrence). No main logical issues; stem allows unique selection of A without contradictions or underspecification, as the question tests knowledge of rechallenge criteria despite not stating initial ILD grade—options provide hypothetical factors. No main medical accuracy issues; aligns with consensus guidelines on T-DXd ILD, emphasizing Grade 1 with resolution as key for rechallenge, while mechanism ties to payload rather than hypersensitivity. Minimal fix: None needed; item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include a 58-year-old woman with metastatic HER2-positive breast cancer who developed drug-induced interstitial lung disease (ILD) on trastuzumab deruxtecan (T-DXd), characterized by progressive dyspnea, bilateral peripheral/lower lobe ground-glass opacities, lymphocytic BAL with low CD4/CD8 ratio, negative infectious workup, and symptom improvement after drug discontinuation and corticosteroids; three months later, restaging shows disease progression, prompting consideration of rechallenge. The clinical problem asks for the factor most strongly supporting T-DXd rechallenge. Discriminating findings imply resolved ILD in progressing cancer, where guidelines favor rechallenge only for prior Grade 1 ILD with complete resolution (option A). Alternatives are inferior: B (anti-drug antibodies not predictive), C (HER2 status irrelevant to ILD risk), D (skin testing not validated for ILD), E (baseline PFTs do not predict recurrence). No main logical issues; stem allows unique selection of A without contradictions or underspecification, as the question tests knowledge of rechallenge criteria despite not stating initial ILD grade—options provide hypothetical factors. No main medical accuracy issues; aligns with consensus guidelines on T-DXd ILD, emphasizing Grade 1 with resolution as key for rechallenge, while mechanism ties to payload rather than hypersensitivity. Minimal fix: None needed; item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-008", "question": "A 42-year-old woman with a history of chronic rhinosinusitis and nasal polyps presents with new-onset asthma requiring systemic corticosteroids. She reports severe reactions to aspirin and ibuprofen characterized by bronchospasm and nasal congestion. She requires hip replacement surgery and the orthopedic surgeon requests clearance for perioperative ketorolac use. After shared decision-making, aspirin desensitization is planned. During the desensitization protocol, she develops bronchospasm at the 60 mg aspirin dose. Which mediator's urinary metabolite would be most elevated during this reaction?", "options": ["Leukotriene E4", "Prostaglandin D2 (as 11β-prostaglandin F2α)", "Histamine (as N-methylhistamine)", "Tryptase", "Platelet-activating factor"], "answer": "A", "answer_index": 0, "explanation": "Aspirin-exacerbated respiratory disease (AERD) is characterized by overproduction of cysteinyl leukotrienes (CysLTs) due to dysregulated arachidonic acid metabolism. During aspirin-induced reactions in AERD, urinary leukotriene E4 (LTE4), the stable end-metabolite of CysLTs, increases dramatically (often 3-10 fold). This distinguishes AERD from IgE-mediated reactions where prostaglandin D2 metabolites and histamine metabolites predominate. Tryptase elevation suggests mast cell degranulation in anaphylaxis but is not characteristic of AERD reactions. The CysLT pathway is the primary driver of bronchoconstriction in AERD.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the patient's history of chronic rhinosinusitis with nasal polyps, new-onset asthma requiring corticosteroids, and severe bronchospasm/nasal congestion reactions to aspirin and ibuprofen, classic for aspirin-exacerbated respiratory disease (AERD). During aspirin desensitization, bronchospasm at 60 mg dose implies a CysLT-driven reaction, making urinary LTE4 (option A) the most elevated metabolite. This is supported by AERD pathophysiology involving overproduction of cysteinyl leukotrienes upon COX-1 inhibition. Alternative choices are worse: B (PGD2) is more IgE-mediated; C (histamine) suggests allergy/anaphylaxis; D (tryptase) indicates mast cell degranulation not primary in AERD; E (PAF) is not characteristically elevated. No main logical issues; the vignette provides sufficient discriminating findings for a single best answer without contradictions or underspecification. No main medical accuracy issues; aligns with current guidelines on AERD, where LTE4 surges 3-10 fold during reactions, distinguishing from other pathways. Minimal fix: N/A, as the item is already unambiguous and accurate; optionally, add 'urinary' to option A for explicitness, though not necessary.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the patient's history of chronic rhinosinusitis with nasal polyps, new-onset asthma requiring corticosteroids, and severe bronchospasm/nasal congestion reactions to aspirin and ibuprofen, classic for aspirin-exacerbated respiratory disease (AERD). During aspirin desensitization, bronchospasm at 60 mg dose implies a CysLT-driven reaction, making urinary LTE4 (option A) the most elevated metabolite. This is supported by AERD pathophysiology involving overproduction of cysteinyl leukotrienes upon COX-1 inhibition. Alternative choices are worse: B (PGD2) is more IgE-mediated; C (histamine) suggests allergy/anaphylaxis; D (tryptase) indicates mast cell degranulation not primary in AERD; E (PAF) is not characteristically elevated. No main logical issues; the vignette provides sufficient discriminating findings for a single best answer without contradictions or underspecification. No main medical accuracy issues; aligns with current guidelines on AERD, where LTE4 surges 3-10 fold during reactions, distinguishing from other pathways. Minimal fix: N/A, as the item is already unambiguous and accurate; optionally, add 'urinary' to option A for explicitness, though not necessary.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-009", "question": "An 82-year-old woman with moderate Alzheimer's dementia (MMSE 18) living in assisted living is hospitalized for community-acquired pneumonia. On hospital day 2, she becomes acutely agitated with visual hallucinations. Her medications include donepezil, memantine, and lisinopril. She is started on haloperidol 0.5 mg for agitation. On day 3, she develops temperature 39.2°C, severe muscle rigidity, diaphoresis, and altered consciousness. Laboratory studies show CK 8,500 U/L and WBC 14,000/μL. Which mechanism best explains this presentation?", "options": ["Anticholinergic toxicity from haloperidol-donepezil interaction", "Dopamine receptor blockade causing neuroleptic malignant syndrome", "Serotonin syndrome from memantine-haloperidol interaction", "Malignant hyperthermia triggered by infection", "Central fever from hypothalamic involvement by infection"], "answer": "B", "answer_index": 1, "explanation": "This patient has developed neuroleptic malignant syndrome (NMS) following haloperidol administration, characterized by the classic tetrad of hyperthermia, severe rigidity, altered mental status, and autonomic instability with elevated CK. Elderly patients with dementia are at increased risk for NMS. The mechanism is dopamine D2 receptor blockade in the hypothalamus and nigrostriatal pathways. While donepezil increases acetylcholine (potentially worsening extrapyramidal symptoms), the presentation is classic for NMS rather than anticholinergic toxicity. Memantine is an NMDA antagonist with minimal serotonergic activity, making serotonin syndrome unlikely.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. The clinical problem asks for the mechanism explaining acute hyperthermia, severe muscle rigidity, diaphoresis, altered consciousness, and elevated CK (8,500 U/L) in an elderly dementia patient after haloperidol initiation for agitation amid pneumonia. Key stem clues: 82-year-old with Alzheimer's (MMSE 18), recent haloperidol for agitation with hallucinations, rapid onset of tetrad symptoms post-antipsychotic, high CK, leukocytosis, background meds (donepezil, memantine, lisinopril). These imply neuroleptic malignant syndrome (NMS) from dopamine blockade. Keyed answer B fits: haloperidol's D2 receptor antagonism in hypothalamus/nigrostriatal pathways causes NMS tetrad; elderly dementia increases risk; no major assumptions needed. Alternatives: A incorrect as haloperidol is anticholinergic but donepezil counters that, and presentation lacks dry skin/delirium dominance; C wrong, memantine lacks serotonergic effects, no SS triad; D implausible without succinylcholine/anesthetics, not infection-triggered; E misses rigidity/CK elevation, fever not central here. No logical issues: stem supports unique best (B) without contradictions or underspecification. Medical accuracy: Consistent with guidelines (e.g., DSM-5 NMS criteria, APA guidance); accurate pathophysiology, risk factors. No inaccuracies. Minimal fix: None needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. The clinical problem asks for the mechanism explaining acute hyperthermia, severe muscle rigidity, diaphoresis, altered consciousness, and elevated CK (8,500 U/L) in an elderly dementia patient after haloperidol initiation for agitation amid pneumonia. Key stem clues: 82-year-old with Alzheimer's (MMSE 18), recent haloperidol for agitation with hallucinations, rapid onset of tetrad symptoms post-antipsychotic, high CK, leukocytosis, background meds (donepezil, memantine, lisinopril). These imply neuroleptic malignant syndrome (NMS) from dopamine blockade. Keyed answer B fits: haloperidol's D2 receptor antagonism in hypothalamus/nigrostriatal pathways causes NMS tetrad; elderly dementia increases risk; no major assumptions needed. Alternatives: A incorrect as haloperidol is anticholinergic but donepezil counters that, and presentation lacks dry skin/delirium dominance; C wrong, memantine lacks serotonergic effects, no SS triad; D implausible without succinylcholine/anesthetics, not infection-triggered; E misses rigidity/CK elevation, fever not central here. No logical issues: stem supports unique best (B) without contradictions or underspecification. Medical accuracy: Consistent with guidelines (e.g., DSM-5 NMS criteria, APA guidance); accurate pathophysiology, risk factors. No inaccuracies. Minimal fix: None needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-010", "question": "A 55-year-old man with cirrhosis secondary to alcohol use disorder and hepatocellular carcinoma (single 3.5 cm lesion, no vascular invasion, AFP 450 ng/mL) undergoes liver transplantation. Explant pathology confirms a single 3.8 cm moderately differentiated HCC without microvascular invasion. Eighteen months post-transplant, surveillance imaging reveals a 2.2 cm lung nodule. Biopsy confirms metastatic HCC. His current immunosuppression includes tacrolimus and mycophenolate mofetil. Which modification to his immunosuppressive regimen is most strongly supported by evidence for managing this recurrence?", "options": ["Conversion from tacrolimus to cyclosporine", "Addition of belatacept to current regimen", "Conversion from tacrolimus to sirolimus", "Discontinuation of all immunosuppression", "Addition of azathioprine to current regimen"], "answer": "C", "answer_index": 2, "explanation": "Conversion from calcineurin inhibitors (tacrolimus) to mTOR inhibitors (sirolimus/everolimus) is recommended in post-transplant HCC recurrence. mTOR inhibitors have direct antitumor effects through inhibition of the PI3K/AKT/mTOR pathway, which is frequently dysregulated in HCC. Multiple studies have shown improved outcomes with mTOR inhibitor-based immunosuppression in HCC recurrence. Complete immunosuppression withdrawal risks allograft rejection without proven oncologic benefit. Cyclosporine, belatacept, and azathioprine lack the antitumor properties of mTOR inhibitors.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 55-year-old post-liver transplant for HCC with confirmed metastatic recurrence in lung (2.2 cm nodule, biopsy-proven); current regimen tacrolimus and mycophenolate; question seeks evidence-supported immunosuppression modification for managing recurrence. These clues imply need for antitumor properties in immunosuppression without risking rejection, pointing to mTOR inhibitors. Main logical issue(s), if any: None; stem provides sufficient details for discrimination—recurrence timing, confirmation, and regimen allow unique selection of C as best, with alternatives lacking antitumor evidence or risking harm. Main medical accuracy issue(s), if any: None; keyed answer aligns with current guidelines (e.g., AASLD, EASL) recommending mTOR inhibitors like sirolimus for post-transplant HCC recurrence due to PI3K/AKT/mTOR pathway inhibition and improved outcomes in studies; alternatives correctly portrayed as inferior (e.g., cyclosporine lacks antitumor effects, discontinuation risks rejection). Item is clinically realistic and board-relevant. Minimal fix: Not needed, as item is already unambiguous and accurate; if enhancing, add 'everolimus' as alternative mTOR in rationale for completeness (though not required).\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 55-year-old post-liver transplant for HCC with confirmed metastatic recurrence in lung (2.2 cm nodule, biopsy-proven); current regimen tacrolimus and mycophenolate; question seeks evidence-supported immunosuppression modification for managing recurrence. These clues imply need for antitumor properties in immunosuppression without risking rejection, pointing to mTOR inhibitors. Main logical issue(s), if any: None; stem provides sufficient details for discrimination—recurrence timing, confirmation, and regimen allow unique selection of C as best, with alternatives lacking antitumor evidence or risking harm. Main medical accuracy issue(s), if any: None; keyed answer aligns with current guidelines (e.g., AASLD, EASL) recommending mTOR inhibitors like sirolimus for post-transplant HCC recurrence due to PI3K/AKT/mTOR pathway inhibition and improved outcomes in studies; alternatives correctly portrayed as inferior (e.g., cyclosporine lacks antitumor effects, discontinuation risks rejection). Item is clinically realistic and board-relevant. Minimal fix: Not needed, as item is already unambiguous and accurate; if enhancing, add 'everolimus' as alternative mTOR in rationale for completeness (though not required).", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-011", "question": "A 48-year-old woman with Crohn's disease on vedolizumab presents with 6 months of progressive fatigue, exertional dyspnea, and paresthesias in her feet. Laboratory studies reveal hemoglobin 8.2 g/dL, MCV 118 fL, reticulocyte count 1.2%, LDH 890 U/L, and indirect bilirubin 2.1 mg/dL. Peripheral smear shows macro-ovalocytes and hypersegmented neutrophils. Vitamin B12 level is 85 pg/mL (normal >200). Anti-intrinsic factor antibodies are negative. She has no history of gastric surgery. Upper endoscopy with gastric biopsy shows chronic atrophic gastritis with intestinal metaplasia but no Helicobacter pylori. Which additional finding would most strongly suggest an autoimmune etiology despite negative anti-IF antibodies?", "options": ["Elevated serum gastrin level >1000 pg/mL", "Presence of anti-parietal cell antibodies", "Low serum pepsinogen I with normal pepsinogen II", "Enterochromaffin-like cell hyperplasia on biopsy", "Positive anti-Saccharomyces cerevisiae antibodies"], "answer": "C", "answer_index": 2, "explanation": "Low serum pepsinogen I (PGI) with normal pepsinogen II (PGII), resulting in a low PGI/PGII ratio, is highly specific for corpus-predominant atrophic gastritis characteristic of autoimmune gastritis. PGI is produced exclusively by chief cells in the corpus, which are destroyed in autoimmune gastritis. Anti-IF antibodies have only 50-70% sensitivity for pernicious anemia. Anti-parietal cell antibodies are more sensitive but less specific. Elevated gastrin and ECL hyperplasia occur in autoimmune gastritis but are consequences rather than diagnostic markers. ASCA is associated with Crohn's disease, not autoimmune gastritis.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include progressive fatigue, dyspnea, paresthesias, macrocytic anemia (Hb 8.2 g/dL, MCV 118 fL), low B12 (85 pg/mL), negative anti-IF antibodies, chronic atrophic gastritis with intestinal metaplasia, no H. pylori, no gastric surgery, and Crohn's disease on vedolizumab—pointing to B12 deficiency from atrophic gastritis, querying strongest evidence for autoimmune etiology. The clinical problem asks for the most suggestive additional finding of autoimmune gastritis despite negative anti-IF. Discriminating findings imply corpus-predominant atrophy; low pepsinogen I with normal II (C) specifically indicates chief cell destruction in autoimmune gastritis. Keyed answer fits as it's highly specific for autoimmune type A gastritis. Alternatives: A (elevated gastrin) and D (ECL hyperplasia) are downstream effects, not diagnostic; B (anti-parietal cell antibodies) is sensitive but less specific; E (ASCA) relates to Crohn's, not gastritis. No main logical issues; stem allows discrimination without contradictions or underspecification. No main medical accuracy issues; aligns with guidelines on autoimmune gastritis diagnostics, where anti-IF sensitivity is 50-70%, and low PGI/PGII ratio is confirmatory. Minimal fix: None needed; item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include progressive fatigue, dyspnea, paresthesias, macrocytic anemia (Hb 8.2 g/dL, MCV 118 fL), low B12 (85 pg/mL), negative anti-IF antibodies, chronic atrophic gastritis with intestinal metaplasia, no H. pylori, no gastric surgery, and Crohn's disease on vedolizumab—pointing to B12 deficiency from atrophic gastritis, querying strongest evidence for autoimmune etiology. The clinical problem asks for the most suggestive additional finding of autoimmune gastritis despite negative anti-IF. Discriminating findings imply corpus-predominant atrophy; low pepsinogen I with normal II (C) specifically indicates chief cell destruction in autoimmune gastritis. Keyed answer fits as it's highly specific for autoimmune type A gastritis. Alternatives: A (elevated gastrin) and D (ECL hyperplasia) are downstream effects, not diagnostic; B (anti-parietal cell antibodies) is sensitive but less specific; E (ASCA) relates to Crohn's, not gastritis. No main logical issues; stem allows discrimination without contradictions or underspecification. No main medical accuracy issues; aligns with guidelines on autoimmune gastritis diagnostics, where anti-IF sensitivity is 50-70%, and low PGI/PGII ratio is confirmatory. Minimal fix: None needed; item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-012", "question": "A 52-year-old man with IgA nephropathy and eGFR 35 mL/min/1.73m² is enrolled in a clinical trial evaluating a novel targeted-release formulation of budesonide (NEFECON). After 9 months of treatment, his 24-hour urine protein decreases from 2.8 g to 0.9 g, and eGFR stabilizes. Repeat kidney biopsy shows reduced mesangial IgA deposits and decreased mesangial hypercellularity. Which mechanism best explains the therapeutic effect of this formulation in IgA nephropathy?", "options": ["Systemic immunosuppression reducing circulating galactose-deficient IgA1", "Direct podocyte stabilization through glucocorticoid receptor activation", "Targeted delivery to Peyer's patches reducing mucosal IgA production", "Inhibition of complement activation at the glomerular level", "Suppression of bone marrow plasma cells producing pathogenic IgA1"], "answer": "C", "answer_index": 2, "explanation": "NEFECON (targeted-release budesonide) is formulated to release budesonide in the distal ileum where Peyer's patches are concentrated. The pathogenesis of IgA nephropathy involves mucosal immune dysregulation with production of galactose-deficient IgA1 (Gd-IgA1) primarily in gut-associated lymphoid tissue (GALT). By targeting Peyer's patches, NEFECON reduces the source of pathogenic Gd-IgA1 production while minimizing systemic corticosteroid exposure due to high first-pass hepatic metabolism. This mucosal-targeted approach distinguishes it from systemic immunosuppression strategies.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: The vignette specifies a 'novel targeted-release formulation of budesonide (NEFECON)' for IgA nephropathy, with post-treatment reductions in 24-hour urine protein (2.8 g to 0.9 g), stabilized eGFR, and biopsy improvements (reduced mesangial IgA deposits and hypercellularity). These clues emphasize the drug's targeted nature and mucosal/gut involvement in IgA nephropathy pathogenesis, pointing to mechanism C (targeted delivery to Peyer's patches reducing mucosal IgA production) as the unique best fit. Alternatives are inferior: A assumes systemic effects contradicted by targeted formulation; B focuses on podocytes, not primary for this drug; D invokes complement, unrelated to budesonide; E targets bone marrow, not gut mucosa.\\nMain logical issue(s), if any: None; the stem provides sufficient discriminating details for a single best answer without contradictions or underspecification.\\nMain medical accuracy issue(s), if any: None; aligns with current understanding of Nefecon's mechanism in IgA nephropathy, targeting gut-associated lymphoid tissue to reduce galactose-deficient IgA1 production, per NEFIGAN/NEFIGARD trials and KDIGO guidelines.\\nMinimal fix: None required; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: The vignette specifies a 'novel targeted-release formulation of budesonide (NEFECON)' for IgA nephropathy, with post-treatment reductions in 24-hour urine protein (2.8 g to 0.9 g), stabilized eGFR, and biopsy improvements (reduced mesangial IgA deposits and hypercellularity). These clues emphasize the drug's targeted nature and mucosal/gut involvement in IgA nephropathy pathogenesis, pointing to mechanism C (targeted delivery to Peyer's patches reducing mucosal IgA production) as the unique best fit. Alternatives are inferior: A assumes systemic effects contradicted by targeted formulation; B focuses on podocytes, not primary for this drug; D invokes complement, unrelated to budesonide; E targets bone marrow, not gut mucosa.\nMain logical issue(s), if any: None; the stem provides sufficient discriminating details for a single best answer without contradictions or underspecification.\nMain medical accuracy issue(s), if any: None; aligns with current understanding of Nefecon's mechanism in IgA nephropathy, targeting gut-associated lymphoid tissue to reduce galactose-deficient IgA1 production, per NEFIGAN/NEFIGARD trials and KDIGO guidelines.\nMinimal fix: None required; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-013", "question": "A 67-year-old man with JAK2 V617F-positive polycythemia vera on hydroxyurea for 8 years presents with progressive splenomegaly, worsening anemia (hemoglobin 8.5 g/dL), and new circulating blasts (6%). Bone marrow biopsy shows 30% cellularity with grade 3 reticulin fibrosis, 8% blasts, and megakaryocyte clustering with atypia. Cytogenetics reveal del(5q), +8, and a new TP53 mutation is detected. Which statement most accurately characterizes his prognosis and optimal management?", "options": ["This represents post-PV myelofibrosis; ruxolitinib will improve survival", "This is post-PV acute myeloid leukemia; intensive chemotherapy is indicated", "This is accelerated phase disease; allogeneic transplant offers best survival", "The TP53 mutation predicts excellent response to hypomethylating agents", "Luspatercept should be initiated for the anemia before other interventions"], "answer": "C", "answer_index": 2, "explanation": "This patient has post-PV myelofibrosis in accelerated phase (10-19% blasts defines accelerated phase; ≥20% defines blast phase/AML). The presence of TP53 mutation, complex cytogenetics including del(5q), and high-risk features confer extremely poor prognosis. Allogeneic stem cell transplantation is the only potentially curative option, though outcomes remain poor with TP53 mutations. Ruxolitinib provides symptomatic benefit but does not improve survival in accelerated/blast phase. TP53 mutations predict poor response to hypomethylating agents and chemotherapy. Luspatercept addresses anemia but not the underlying disease progression.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (primary); U (secondary, as assuming non-standard blast threshold for 'accelerated' is needed to defend C). Verdict on keyed answer: Miskeyed. Key stem clues that drive a unique best answer: JAK2+ PV history, progressive splenomegaly, anemia (Hb 8.5 g/dL), 6% circulating blasts, BM with 30% cellularity, grade 3 fibrosis, 8% blasts, atypical megakaryocytes, del(5q), +8, new TP53 mutation—these indicate high-risk post-PV myelofibrosis in chronic phase (blasts <10%), with poor prognosis; clues fail to support 'accelerated phase' (requires 10-19% blasts). Main logical issue(s): Keyed C mischaracterizes as accelerated phase, which contradicts standard definitions and stem's blast percentages; a unique best exists (A, correctly identifying post-PV MF and ruxolitinib's survival benefit in chronic phase), but key mismatches it, fitting 'K' (miskeyed); secondary 'U' since defending C requires unstated assumption of lower blast threshold. Main medical accuracy issue(s): Item and rationale inaccurately classify 8% blasts as accelerated phase, contradicting consensus (IWG-MRT/WHO: 10-19% for accelerated MPN); TP53 and complex cytogenetics correctly imply poor prognosis, but misphasing could mislead on staging and urgency. Minimal fix: Revise stem to '18% blasts' in bone marrow to align with accelerated phase definition, making C defensible and key correct.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (primary); U (secondary, as assuming non-standard blast threshold for 'accelerated' is needed to defend C). Verdict on keyed answer: Miskeyed. Key stem clues that drive a unique best answer: JAK2+ PV history, progressive splenomegaly, anemia (Hb 8.5 g/dL), 6% circulating blasts, BM with 30% cellularity, grade 3 fibrosis, 8% blasts, atypical megakaryocytes, del(5q), +8, new TP53 mutation—these indicate high-risk post-PV myelofibrosis in chronic phase (blasts <10%), with poor prognosis; clues fail to support 'accelerated phase' (requires 10-19% blasts). Main logical issue(s): Keyed C mischaracterizes as accelerated phase, which contradicts standard definitions and stem's blast percentages; a unique best exists (A, correctly identifying post-PV MF and ruxolitinib's survival benefit in chronic phase), but key mismatches it, fitting 'K' (miskeyed); secondary 'U' since defending C requires unstated assumption of lower blast threshold. Main medical accuracy issue(s): Item and rationale inaccurately classify 8% blasts as accelerated phase, contradicting consensus (IWG-MRT/WHO: 10-19% for accelerated MPN); TP53 and complex cytogenetics correctly imply poor prognosis, but misphasing could mislead on staging and urgency. Minimal fix: Revise stem to '18% blasts' in bone marrow to align with accelerated phase definition, making C defensible and key correct.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-014", "question": "A 35-year-old man presents with recurrent bacterial sinopulmonary infections and chronic norovirus gastroenteritis. Laboratory evaluation reveals IgG 320 mg/dL, IgA 45 mg/dL, IgM 25 mg/dL, and absent specific antibody responses to pneumococcal polysaccharide and protein antigens despite vaccination. B-cell numbers are normal. Genetic testing reveals a heterozygous mutation in NFKB1. His 8-year-old daughter has similar symptoms. Which additional clinical manifestation is most characteristically associated with this genetic defect?", "options": ["Severe combined immunodeficiency in infancy", "Autoimmune cytopenias and lymphoproliferation", "Hyper-IgE syndrome with eczema and bone abnormalities", "Complement deficiency with recurrent Neisseria infections", "Chronic granulomatous disease with catalase-positive organisms"], "answer": "B", "answer_index": 1, "explanation": "NFKB1 haploinsufficiency is an autosomal dominant cause of common variable immunodeficiency (CVID). Beyond hypogammaglobulinemia and recurrent infections, NFKB1 deficiency is strongly associated with autoimmune manifestations, particularly autoimmune cytopenias (autoimmune hemolytic anemia, ITP) and lymphoproliferation including splenomegaly and lymphadenopathy. NF-κB signaling is critical for B-cell survival, class-switch recombination, and immune tolerance. The autosomal dominant inheritance pattern explains the affected daughter. SCID, hyper-IgE, complement deficiency, and CGD have distinct genetic etiologies and clinical presentations.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include adult-onset recurrent bacterial sinopulmonary infections and chronic norovirus gastroenteritis, hypogammaglobulinemia (IgG 320 mg/dL, IgA 45 mg/dL, IgM 25 mg/dL), absent specific antibody responses despite vaccination, normal B-cell numbers, heterozygous NFKB1 mutation, and autosomal dominant inheritance evidenced by the affected 8-year-old daughter. These point to NFKB1 haploinsufficiency as a cause of common variable immunodeficiency (CVID) with characteristic autoimmune features. No main logical issues; the stem is internally consistent, supports B as the single best answer by associating NFKB1 defects with autoimmune cytopenias and lymphoproliferation, while alternatives represent distinct immunodeficiencies (A: SCID typically presents in infancy with T/B defects; C: Hyper-IgE involves STAT3 mutations and elevated IgE; D: Complement deficiencies feature encapsulated bacterial/Neisseria infections without hypogammaglobulinemia; E: CGD involves phagocyte defects and catalase-positive infections). Main medical accuracy issues: None; aligns with current understanding of NFKB1 mutations causing CVID-like syndrome with prominent autoimmunity, per mainstream immunology guidelines. Minimal fix: N/A as item is unambiguous and accurate, though optionally adding 'autosomal dominant' to stem could reinforce inheritance clue without altering validity.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include adult-onset recurrent bacterial sinopulmonary infections and chronic norovirus gastroenteritis, hypogammaglobulinemia (IgG 320 mg/dL, IgA 45 mg/dL, IgM 25 mg/dL), absent specific antibody responses despite vaccination, normal B-cell numbers, heterozygous NFKB1 mutation, and autosomal dominant inheritance evidenced by the affected 8-year-old daughter. These point to NFKB1 haploinsufficiency as a cause of common variable immunodeficiency (CVID) with characteristic autoimmune features. No main logical issues; the stem is internally consistent, supports B as the single best answer by associating NFKB1 defects with autoimmune cytopenias and lymphoproliferation, while alternatives represent distinct immunodeficiencies (A: SCID typically presents in infancy with T/B defects; C: Hyper-IgE involves STAT3 mutations and elevated IgE; D: Complement deficiencies feature encapsulated bacterial/Neisseria infections without hypogammaglobulinemia; E: CGD involves phagocyte defects and catalase-positive infections). Main medical accuracy issues: None; aligns with current understanding of NFKB1 mutations causing CVID-like syndrome with prominent autoimmunity, per mainstream immunology guidelines. Minimal fix: N/A as item is unambiguous and accurate, though optionally adding 'autosomal dominant' to stem could reinforce inheritance clue without altering validity.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-015", "question": "A 45-year-old woman from rural Peru presents with a 3-month history of progressive dysphagia, regurgitation, and 20-pound weight loss. Barium swallow shows a dilated esophagus with smooth tapering at the gastroesophageal junction (\"bird's beak\" appearance). Esophageal manometry reveals absent peristalsis and incomplete lower esophageal sphincter relaxation. Serologic testing for Trypanosoma cruzi is positive. Cardiac evaluation shows a dilated left ventricle with apical aneurysm and EF 35%. Which statement best characterizes the pathophysiology linking her esophageal and cardiac findings?", "options": ["Direct parasitic invasion of smooth muscle cells in both organs", "Autoimmune destruction of intramural neurons and cardiac myocytes", "Eosinophilic infiltration causing tissue fibrosis", "Vasculitis affecting the vasa nervorum and coronary arteries", "Toxin-mediated damage similar to diphtheria"], "answer": "B", "answer_index": 1, "explanation": "Chronic Chagas disease (American trypanosomiasis) causes megaesophagus and cardiomyopathy through autoimmune mechanisms. Molecular mimicry between T. cruzi antigens and host cardiac myosin, neuronal proteins, and other self-antigens triggers autoimmune destruction of intramural ganglion cells (Auerbach's plexus) in the esophagus and cardiac myocytes/conduction tissue. The apical aneurysm is pathognomonic for Chagas cardiomyopathy. Direct parasitic invasion occurs in acute phase but parasites are rarely found in chronic lesions. The pathology is characterized by lymphocytic infiltration and fibrosis, not eosinophilia or vasculitis.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include rural Peru origin, progressive dysphagia/regurgitation/weight loss, barium swallow showing dilated esophagus with bird's beak tapering, manometry with absent peristalsis and incomplete LES relaxation, positive T. cruzi serology, and cardiac findings of dilated left ventricle with apical aneurysm and EF 35%, collectively pointing to chronic Chagas disease with megaesophagus and cardiomyopathy. The question asks for the pathophysiology linking these, best explained by autoimmune destruction (B) via molecular mimicry targeting intramural neurons and cardiac myocytes. No main logical issues; stem is consistent, supports unique best answer without contradictions or underspecification. Alternatives are inferior: A reflects acute phase only; C lacks eosinophilia evidence; D not typical of Chagas; E mimics unrelated toxin. No main medical accuracy issues; aligns with current understanding of chronic Chagas as autoimmune-mediated, with parasites rare in chronic lesions, per major guidelines (e.g., WHO, AHA). Item is clinically realistic and board-relevant. Minimal fix: No edit required, as item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include rural Peru origin, progressive dysphagia/regurgitation/weight loss, barium swallow showing dilated esophagus with bird's beak tapering, manometry with absent peristalsis and incomplete LES relaxation, positive T. cruzi serology, and cardiac findings of dilated left ventricle with apical aneurysm and EF 35%, collectively pointing to chronic Chagas disease with megaesophagus and cardiomyopathy. The question asks for the pathophysiology linking these, best explained by autoimmune destruction (B) via molecular mimicry targeting intramural neurons and cardiac myocytes. No main logical issues; stem is consistent, supports unique best answer without contradictions or underspecification. Alternatives are inferior: A reflects acute phase only; C lacks eosinophilia evidence; D not typical of Chagas; E mimics unrelated toxin. No main medical accuracy issues; aligns with current understanding of chronic Chagas as autoimmune-mediated, with parasites rare in chronic lesions, per major guidelines (e.g., WHO, AHA). Item is clinically realistic and board-relevant. Minimal fix: No edit required, as item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-016", "question": "A 62-year-old man with metastatic melanoma harboring BRAF V600E mutation has disease progression on combination dabrafenib/trametinib after 14 months. He is started on pembrolizumab. After 4 cycles, restaging shows mixed response with regression of most lesions but growth of a single hepatic metastasis. Biopsy of the progressing lesion reveals loss of β2-microglobulin expression. Which mechanism best explains resistance to pembrolizumab in this lesion?", "options": ["Upregulation of alternative immune checkpoints (LAG-3, TIM-3)", "Defective antigen presentation via MHC class I pathway", "Increased regulatory T-cell infiltration in the tumor microenvironment", "Activation of the WNT/β-catenin pathway excluding T-cells", "Loss of tumor neoantigens through immunoediting"], "answer": "B", "answer_index": 1, "explanation": "β2-microglobulin (B2M) is essential for MHC class I complex assembly and surface expression. Loss of B2M results in absent MHC class I expression, preventing CD8+ T-cell recognition of tumor antigens regardless of PD-1/PD-L1 blockade. This is a well-characterized mechanism of acquired resistance to checkpoint inhibitors. While alternative checkpoints, Tregs, WNT/β-catenin activation, and neoantigen loss can all contribute to immunotherapy resistance, the specific finding of B2M loss directly implicates defective MHC class I antigen presentation as the primary resistance mechanism in this lesion.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the patient's metastatic melanoma with BRAF V600E mutation, progression on dabrafenib/trametinib, initiation of pembrolizumab, mixed response after 4 cycles with regression of most lesions but growth of a single hepatic metastasis, and biopsy revealing loss of β2-microglobulin (B2M) expression in the progressing lesion. These clues specifically implicate defective MHC class I antigen presentation due to B2M loss, as B2M is essential for MHC class I assembly, preventing CD8+ T-cell recognition despite PD-1 blockade. No main logical issues; the item is coherent, supports a unique best answer (B), and the key matches it without contradictions or underspecification. No main medical accuracy issues; the mechanism aligns with established oncology knowledge on acquired resistance to checkpoint inhibitors, consistent with current guidelines and literature (e.g., defects in antigen presentation pathways). The rationale correctly prioritizes B2M loss over other plausible but less directly linked mechanisms like alternative checkpoints or neoantigen loss. Minimal fix: None needed, as the item is already unambiguous and accurate; however, to enhance clarity, add 'due to B2M loss' explicitly in option B for reinforcement.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the patient's metastatic melanoma with BRAF V600E mutation, progression on dabrafenib/trametinib, initiation of pembrolizumab, mixed response after 4 cycles with regression of most lesions but growth of a single hepatic metastasis, and biopsy revealing loss of β2-microglobulin (B2M) expression in the progressing lesion. These clues specifically implicate defective MHC class I antigen presentation due to B2M loss, as B2M is essential for MHC class I assembly, preventing CD8+ T-cell recognition despite PD-1 blockade. No main logical issues; the item is coherent, supports a unique best answer (B), and the key matches it without contradictions or underspecification. No main medical accuracy issues; the mechanism aligns with established oncology knowledge on acquired resistance to checkpoint inhibitors, consistent with current guidelines and literature (e.g., defects in antigen presentation pathways). The rationale correctly prioritizes B2M loss over other plausible but less directly linked mechanisms like alternative checkpoints or neoantigen loss. Minimal fix: None needed, as the item is already unambiguous and accurate; however, to enhance clarity, add 'due to B2M loss' explicitly in option B for reinforcement.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-017", "question": "A 28-year-old woman with allergic rhinitis and mild persistent asthma on fluticasone/salmeterol presents for evaluation of recurrent anaphylaxis. She has experienced three episodes of anaphylaxis in the past year, each occurring 2-4 hours after eating, with no consistent food trigger identified. Episodes are characterized by flushing, hypotension, and abdominal cramping. Baseline serum tryptase is 6 ng/mL (normal <11.4). Skin prick testing to common food allergens is negative. During her most recent episode, serum tryptase was 28 ng/mL. Bone marrow biopsy shows scattered atypical mast cells expressing CD25. KIT D816V mutation is detected. Which diagnostic criterion confirms systemic mastocytosis in this patient?", "options": ["Elevated acute tryptase level during anaphylaxis", "Presence of CD25-positive mast cells on bone marrow biopsy", "Detection of KIT D816V mutation", "Baseline tryptase level above 20 ng/mL", "Multifocal dense mast cell aggregates (>15 mast cells) in bone marrow"], "answer": "E", "answer_index": 4, "explanation": "Diagnosis of systemic mastocytosis requires either the major criterion (multifocal dense aggregates of ≥15 mast cells in bone marrow or extracutaneous tissue) OR three minor criteria. Minor criteria include: >25% spindle-shaped/atypical mast cells, KIT D816V mutation, CD25/CD2 expression on mast cells, and baseline tryptase >20 ng/mL. This patient has two minor criteria (CD25 expression and KIT mutation) but needs either the major criterion or one more minor criterion. Her baseline tryptase of 6 ng/mL does not meet the minor criterion threshold. Finding dense mast cell aggregates (major criterion) would definitively confirm the diagnosis.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: N (secondary U). Verdict on keyed answer: No defensible answer. Key stem clues that drive (or fail to drive) a unique best answer: recurrent anaphylaxis 2-4 hours post-eating without food trigger, normal baseline tryptase (6 ng/mL), elevated tryptase during episode (28 ng/mL), negative food skin testing, bone marrow with scattered atypical CD25+ mast cells, KIT D816V mutation. These suggest SM but provide only two minor criteria (CD25 expression, KIT mutation), lacking major criterion (dense aggregates) or third minor (e.g., baseline tryptase >20 ng/mL or quantified >25% atypical mast cells). Main logical issue(s): No option can be defended as confirming SM in this patient, as the vignette does not establish the diagnosis (no major criterion met, only two minors); question asks for criterion that 'confirms' but none do based on given details (N). Secondarily, 'scattered atypical' is underspecified regarding minor criterion 1 (>25% atypical in infiltrate), requiring assumption (U). Main medical accuracy issue(s): None; vignette and rationale align with WHO diagnostic criteria for SM, including major/minor criteria details. Minimal fix: Revise question stem to 'Which diagnostic criterion would confirm systemic mastocytosis in this patient?' to make E the unique best answer as the missing major criterion.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"N\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N (secondary U). Verdict on keyed answer: No defensible answer. Key stem clues that drive (or fail to drive) a unique best answer: recurrent anaphylaxis 2-4 hours post-eating without food trigger, normal baseline tryptase (6 ng/mL), elevated tryptase during episode (28 ng/mL), negative food skin testing, bone marrow with scattered atypical CD25+ mast cells, KIT D816V mutation. These suggest SM but provide only two minor criteria (CD25 expression, KIT mutation), lacking major criterion (dense aggregates) or third minor (e.g., baseline tryptase >20 ng/mL or quantified >25% atypical mast cells). Main logical issue(s): No option can be defended as confirming SM in this patient, as the vignette does not establish the diagnosis (no major criterion met, only two minors); question asks for criterion that 'confirms' but none do based on given details (N). Secondarily, 'scattered atypical' is underspecified regarding minor criterion 1 (>25% atypical in infiltrate), requiring assumption (U). Main medical accuracy issue(s): None; vignette and rationale align with WHO diagnostic criteria for SM, including major/minor criteria details. Minimal fix: Revise question stem to 'Which diagnostic criterion would confirm systemic mastocytosis in this patient?' to make E the unique best answer as the missing major criterion.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-018", "question": "An 85-year-old man with heart failure with preserved ejection fraction, chronic kidney disease stage 3b, and type 2 diabetes is hospitalized for acute decompensated heart failure. He is treated with IV diuretics with good response. Prior to discharge, his medications are reviewed. His current regimen includes lisinopril 10 mg daily, metoprolol succinate 50 mg daily, empagliflozin 10 mg daily, and furosemide 40 mg twice daily. His eGFR is 38 mL/min/1.73m², potassium 4.8 mEq/L, and NT-proBNP 1,850 pg/mL (down from 5,200 on admission). Which medication adjustment is most strongly supported by evidence to reduce mortality in this patient?", "options": ["Add spironolactone 25 mg daily", "Increase lisinopril to 20 mg daily", "Add sacubitril/valsartan in place of lisinopril", "Add finerenone 10 mg daily", "Continue current regimen without changes"], "answer": "A", "answer_index": 0, "explanation": "The TOPCAT trial (Americas cohort) demonstrated mortality benefit with spironolactone in HFpEF. More importantly, the 2023 focused update to HF guidelines recommends MRAs (spironolactone/eplerenone) as a Class IIa recommendation for HFpEF to reduce hospitalizations. While finerenone has shown benefits in diabetic kidney disease, its role in HFpEF is less established than traditional MRAs. Sacubitril/valsartan (PARAGON-HF) showed benefit primarily in women and those with EF at the lower end of the HFpEF spectrum. With potassium 4.8 and eGFR 38, spironolactone can be safely initiated with monitoring. SGLT2 inhibitor is already optimized.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: 85-year-old with HFpEF, CKD stage 3b (eGFR 38), T2DM, elevated NT-proBNP (1850 pg/mL), potassium 4.8 mEq/L, on lisinopril, metoprolol, empagliflozin, furosemide; question seeks evidence-based adjustment to reduce mortality. Clues support adding MRA for HFpEF per guidelines, with safe initiation given labs.\\nMain logical issue(s), if any: None; stem allows discrimination of A as unique best, as alternatives require unstated assumptions (e.g., albuminuria for D) or have weaker evidence for mortality in HFpEF.\\nMain medical accuracy issue(s), if any: Keyed answer (A) aligns with 2022 AHA/ACC/HFSA guidelines (Class 2a for MRAs in HFpEF to reduce hospitalizations) and TOPCAT Americas subgroup showing mortality benefit (CV mortality HR 0.74, p=0.01). However, overall TOPCAT trial did not show significant mortality reduction, representing a nuance; finerenone (D) has CV mortality benefit in T2DM CKD (FIDELITY HR 0.86, p=0.034) but requires albuminuria (unstated in stem). ARNI (C) has marginal, subgroup-specific benefits in HFpEF without strong mortality data.\\nMinimal fix: Add 'with microalbuminuria' to stem to enable evaluation of D, or rekey to D if emphasizing DKD mortality evidence.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: 85-year-old with HFpEF, CKD stage 3b (eGFR 38), T2DM, elevated NT-proBNP (1850 pg/mL), potassium 4.8 mEq/L, on lisinopril, metoprolol, empagliflozin, furosemide; question seeks evidence-based adjustment to reduce mortality. Clues support adding MRA for HFpEF per guidelines, with safe initiation given labs.\nMain logical issue(s), if any: None; stem allows discrimination of A as unique best, as alternatives require unstated assumptions (e.g., albuminuria for D) or have weaker evidence for mortality in HFpEF.\nMain medical accuracy issue(s), if any: Keyed answer (A) aligns with 2022 AHA/ACC/HFSA guidelines (Class 2a for MRAs in HFpEF to reduce hospitalizations) and TOPCAT Americas subgroup showing mortality benefit (CV mortality HR 0.74, p=0.01). However, overall TOPCAT trial did not show significant mortality reduction, representing a nuance; finerenone (D) has CV mortality benefit in T2DM CKD (FIDELITY HR 0.86, p=0.034) but requires albuminuria (unstated in stem). ARNI (C) has marginal, subgroup-specific benefits in HFpEF without strong mortality data.\nMinimal fix: Add 'with microalbuminuria' to stem to enable evaluation of D, or rekey to D if emphasizing DKD mortality evidence.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}]